To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma

Inclusion Criteria:

Patients must meet all of the following inclusion criteria to be enrolled：

• Age range: 18 to 80 years old (inclusive), both male and female are acceptable；
• ECOG: 0-2；
• B-cell non-Hodgkin's lymphoma expressing CD20 antigen that has been pathologically diagnosed；
• At least one measurable lesion meeting the criteria specified in the Lugano 2014 response assessment； Acceptable organ function at screening；

Exclusion Criteria:

• A history of severe allergy to monoclonal antibody therapy (or recombinant antibody-related fusion protein)；
• Previously received CD20-CD3 bispecific antibody treatment；
• Previous allogeneic hematopoietic stem cell transplantation；
• Previous solid organ transplantation；
• History of autoimmune diseases；
• Patients with a history of macrophage activation syndrome (MAS)/ hemophagocytic lymphohistiocytosis (HLH)；
• Patients with a history of progressive multifocal leukoencephalopathy (PML)；
• A known or suspected history of CNS lymphoma (including primary or secondary)；
• There is pleural effusion, peritoneal effusion or pericardial effusion that requires treatment (such as puncture or drainage)；